BioPerspectives

Jun 19, 2008

Implications of GINA for the Biotech and Pharma Industries

  • President Bush's recent signing into law of the Genetic Information Nondiscrimination Act (GINA) is not only a victory for individuals but for biotech and pharmaceutical companies as well. GINA is the first and only federal legislation that will provide protection against discrimination based on an individual's genetic information in health insurance coverage and employment settings.

    During this week's GEN podcast, Sharon Terry, from the Genetic Alliance, discusses how GINA will allow the promise of genetic testing and disease management and prevention to be more fully realized. She explores both the implications of GINA's passage for companies carrying out biotech or pharmaceutical research and the opportunities that GINA opens up for these companies. Terry also explains how the overall U.S. healthcare system and companies specifically involved in the development of personalized medicine will be impacted by GINA.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.